Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.

Overview of attention for article published in Annals of Internal Medicine, December 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 5 news outlets
twitter: 9 X users
facebook: 1 Facebook page

reddit: 1 Redditor
bluesky: 5 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 10 Mendeley

So far, Altmetric has seen 5 news stories from 5 outlets.

Grippewelle in Europa; so wirksam sind Influenza-Vakzine 2025/2026

Medscape, 08 Jan 2026

Im Infektiologie-Blog bieten wir Ihnen jede Woche eine kurze Übersicht zu den aktuellen Entwicklungen in der Epidemiologie…

Phase-II-Studie: Orale HIV-Therapie einmal wöchentlich für bessere Adhärenz

Pharmazeutische Zeitung, 30 Dec 2025

An der von Gilead Sciences gesponserten Phase-II-Studie nahmen 104 Patientinnen und Patienten mit HIV-1 teil, die bislang eine…

Once-Weekly Oral Islatravir Plus Lenacapavir Maintains HIV Suppression Through 48 Weeks

Contagion Live , 23 Dec 2025

Once-weekly oral islatravir (ISL) 2 mg plus lenacapavir (LEN) 300 mg maintained high rates of virologic suppression through 48…

Weekly islatravir plus lenacapavir maintains HIV virologic suppression | 2 Minute Medicine

2 Minute Medicine , 22 Dec 2025

1. In this randomized controlled trial, once-weekly oral islatravir (ISL) plus lenacapavir (LEN) maintained high rates of HIV-1…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.